Flash Finance

Samsrita Labs Ltd539267Corporate

Healthcare Service Provider Latest results: Mar 2026 13 quarters of data
Consolidated Standalone
₹12.25
MCap ₹28 Cr
Samsrita Labs Ltd — Stock analysis & AI research Samsrita Labs Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹0 Cr
Sales · Mar 2026
₹-0 Cr
Operating Profit · Mar 2026
-66.7% YoY
-750.0%
OPM % · Mar 2026
₹-0 Cr
Net Profit · Mar 2026
-33.3% YoY
₹-0.05
EPS · Mar 2026
+16.7% YoY

📝 Samsrita Labs Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Samsrita Labs Ltd reported revenue of ₹0 crore for the quarter ended March 2026 (Q4 FY26).

The company reported a net loss of ₹0 crore, against a net loss of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.05.

Operating profit stood at ₹-0 crore — an operating margin (OPM) of -750.0%.

Full year and trailing twelve months

For the full year FY26, Samsrita Labs Ltd posted revenue of ₹0 crore, with a net loss of ₹9 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹0 crore with a net loss of ₹9 crore.

Valuation snapshot

At the current price of ₹12.25, 539267 has a market capitalisation of ₹28 crore.

Within the Healthcare Service Provider industry, it is the 11th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 25.44%, public shareholders 74.57% of Samsrita Labs Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹28 Cr
Current Price ?
₹12.2
P/E ?
N/A
Industry P/E ?
22.50
P/B ?
2.46
P/S ?
1,393.44
P/FCF ?
-15.83
Enterprise Value ?
₹30 Cr
EV/EBITDA ?
-3.39
PEG ?
N/A
Earnings Yield ?
-29.5%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹0 Cr
OPM ?
-43,600.0%
Profit after tax (TTM) ?
₹-9 Cr
EPS (TTM) ?
₹-3.82
ROCE ?
-63.1%
ROE ?
-76.7%
ROA ?
-62.3%
Growth
Sales — latest qtr ?
₹0 Cr
PAT — latest qtr ?
₹-0 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
-33.3%
Sales growth (3y) ?
0%
Sales growth (5y) ?
15%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹2 Cr
Debt to Equity ?
0.15
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
25.44%
Change in promoter holding ?
-22.81%
Pledged percentage ?
N/A
Market
Return 3 months ?
-13.2%
Return 6 months ?
-21.7%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 0000000000000 — —
Operating Profit -1-0-0-0-0-0-0-0-0-0-5-3-0 -66.7% +95.5%
Other Income 0000000000000 — —
Interest 0000000000000 — —
Depreciation 0000000000000 — —
Profit Before Tax -1-0-0-0-0-0-0-0-0-0-5-3-0 -33.3% +96.4%
Net Profit -1-0-0-0-0-0-0-0-0-0-5-3-0 -33.3% +96.4%
EPS -0.44-0.06-0.03-0.03-0.05-0.06-0.03-0.03-0.06-0.19-2.17-1.48-0.05 +16.7% +96.6%
OPM % -4000.0% — — — — — — — — — — — -750.0% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹0 Cr ₹0 Cr ₹0 Cr —
Operating Profit ₹-0 Cr ₹-9 Cr ₹-9 Cr -3253.8%
OPM % — -43,600.00% -43,600.00% —
NPM % — -43,500.00% -43,500.00% —
Other Income ₹0 Cr ₹0 Cr ₹0 Cr —
Depreciation ₹0 Cr ₹0 Cr ₹0 Cr —
Interest ₹0 Cr ₹0 Cr ₹0 Cr —
EBIT ₹-0 Cr ₹-9 Cr ₹-9 Cr -3253.8%
PBT ₹-0 Cr ₹-9 Cr ₹-9 Cr -3242.3%
Tax — — — —
Net Profit ₹-0 Cr ₹-9 Cr ₹-9 Cr -3246.2%
EPS ₹-0.18 ₹-3.89 ₹-3.89 -2061.1%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14.8114.8114.8122.75 +53.6%
Reserves -2.22-2.47-2.72-11.41 -319.5%
Borrowings 2.082.202.431.66 -31.7%
Other Liabilities 0.961.101.160.97 -16.4%
Total Liabilities 15.6315.6415.6813.97 -10.9%
Fixed Assets 0.010.010.002.00 —
CWIP 3.263.263.260.00 -100.0%
Investments 4.874.874.879.42 +93.4%
Other Assets 7.497.507.552.55 -66.2%
Total Assets 15.6315.6415.6813.97 -10.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 0.66-0.13-0.23-5.02 -2082.6%
Cash from Investing Activity 0.000.000.003.26 —
Cash from Financing Activity -0.670.130.223.39 +1440.9%
Net Cash Flow 0.000.000.001.63 —
Free Cash Flow 0.66-0.13-0.23-1.76 -665.2%
CFO/OP -67%52%88%58% -34.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 38,325.00——365.00 —
Inventory Days 0.00——0.00 —
Cash Conversion Cycle 38,325.00——365.00 —
Working Capital Days 46,172.50——-29,747.50 —
ROCE % -4.56%-1.71%-1.79%-63.08% -3424.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 48.25%31.41%25.44%25.44% +0.0%
Public 51.74%68.58%74.56%74.57% +0.0%
No. of Shareholders 2,4782,4412,4362,441 +0.2%

⚖️ Peer comparison

Industry: Healthcare Service Provider · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 NEPHROPLUS Nephrocare Health ₹673.00 6,768 78.9 1,054 85 22.8% 8.1% — — 23.6% 33.2%
2 532067 3B BlackBio ₹1,205.90 1,166 18.8 153 56 34.9% 36.7% 47.1% 25.7% 50.7% -29.0%
3 514330 One Global ₹139.00 1,043 3.7 513 74 19.1% 14.5% 311.6% 288.9% 16.8% 43.0%
4 HEALTHX Health X ₹306.95 976 — 0 -1 -390.4% -376.2% — — -20.0% -367.5%
5 526546 Choksi Laboratories ₹61.93 146 19.9 47 2 26.8% 4.6% 10.1% 28.8% 7.5% 49.3%
6 540788 Aspira Pathlab ₹31.00 107 — 26 -0 3.8% -1.7% 13.5% -97.1% 17.5% -108.5%
7 530897 NG Industries ₹165.30 39 28.7 17 2 11.1% 11.4% -0.9% -77.7% 13.8% 104.3%
8 524602 Bandaram Pharma ₹30.99 33 162.8 79 1 4.8% 1.5% 70.2% -46.9% 195.7% 3322.0%
9 524548 Sharma East ₹50.09 32 13.9 37 1 9.6% 3.2% 20.3% 0.0% 13.7% -18.7%
10 542248 Deccan Health ₹35.53 30 34.8 82 3 6.4% 3.1% 9.1% 115.7% -0.3% 21.3%
11 539267 Samsrita Labs ₹17.13 28 — — — — — — — — —
12 523489 Chennai Meenakshi ₹34.47 28 — 37 -0 1.5% -1.1% 6.4% 16.1% -0.7% 100.4%
13 539428 Tejnaksh Healthcare ₹23.46 27 38.5 11 1 26.5% 11.3% -16.3% -47.5% 0.5% 24.1%
14 526139 Transgene Biotek ₹9.56 21 — 0 -2 -223.0% -766.2% -25.9% -146.3% 20.0% 9.5%
15 516110 Family Care ₹7.44 11 — 0 -8 -1321.3% -3505.7% -97.3% 80.3% 150.0% 39.5%
16 534422 Looks Health ₹5.73 10 177.4 0 0 41.2% 7.5% -2.6% 0.0% 75.7% —
17 531043 Dhanvantri Jeevan ₹19.95 10 16.1 28 1 3.2% 1.8% 14.2% -23.5% 41.6% 200.0%
18 526504 Dolphin Medical ₹1.85 10 5.2 1 0 13.0% 7.4% -2.6% 333.3% 21.2% -40.7%
19 541299 Dr Lalchandani ₹27.60 7 345.0 4 0 9.3% 1.7% — — -8.6% -148.1%
20 526187 Ashram Online.Com ₹6.29 7 — 1 -0 -74.9% -20.3% 33.3% -71.4% 31.6% 40.2%
❓ Frequently asked questions
What was Samsrita Labs Ltd's revenue in Q4 FY26?
Samsrita Labs Ltd reported revenue of ₹0 crore for the quarter ended March 2026 (Q4 FY26).
What was Samsrita Labs Ltd's net profit in Q4 FY26?
The company reported a net loss of ₹0 crore, against a net loss of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.05.
What is 539267's market capitalisation and P/E ratio?
At the current price of ₹12.25, 539267 has a market capitalisation of ₹28 crore.
Who owns Samsrita Labs Ltd? (shareholding pattern)
As of Mar 2026, promoters held 25.44%, public shareholders 74.57% of Samsrita Labs Ltd.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI